The biggest risk, at this point, is the emergence of vaccine-resistant new strains of the virus
Of course, let’s not kid ourselves: none of this is will imply a straightforward path ahead. First, the distribution of vaccines has had a slow start in most countries. Second, the win of the two Georgia Senate seats on 5 January 2021 implies a de facto ‘blue’ majority, given the tie-break vote of Vice President Harris. Yet, this does not offer free reign to the Biden administration on all of its planned policies, as the administration’s legislative proposals could be blocked in the Senate by filibuster.
While we recognize the hurdles ahead, we believe that neither of the two issues are reasons enough to change our supportive stance on global equities. They could, however, cause occasional negative market reaction. As we have maintained for the last few quarters, the Covid-19 outbreak and its impact on the economic recovery remain the key drivers behind equity markets.
The amount of resources put in by governments and the healthcare community to increase the vaccination rates worldwide is unprecedented. This bodes well for rapid improvement, although certainly not at light speed. The biggest risk, at this point, is the emergence of vaccine-resistant new strains of the virus. Thus far, this does not appear to be the case.
The result of the Georgia run-offs has changed the investment playground for equity investors, arguably for the better. Within the limits and implications of potential filibuster, large parts of the Biden administration’s agenda can be achieved with a slim majority in Congress. This includes the approval of policymakers, as well as more stimulus, environmental policies and changes to the US healthcare system than we would have had with a divided Congress.
Of course, the amount of funding for stimulus, climate and healthcare initiatives will be limited by the need for a budget reconciliation process. This is not a bad outcome for equity markets, as it will actually provide a silver lining for US investors concerned by the more left-leaning potential policies of a Democratic administration. From this point of view, we have moved to a ‘Goldilocks’ scenario. Not too hot, not too cold.
There are two areas within equities, however, where we could see a tangible negative impact. First and foremost, with the approval of policymakers being only dependent on a simple Senate majority and not affected by filibuster, we are likely to see nominations that will bring more regulatory scrutiny on the financial sector, big data, and high environmental impact industries. For the financial industry in particular, the negative effect of higher scrutiny could be offset by the benefits of an economic rebound, but it will all depend on degrees of magnitude.
The other area of potentially negative impact will be healthcare. Given the narrow Congress majority, the outcome of the US elections is still broadly positive overall for the healthcare sector, with radical reform likely to be off the agenda. However, within healthcare subsectors, the impact will be different.
For example, life science tools companies are likely to benefit from increased funding to support the US academic research base, particularly given the on-going pandemic. Conversely, we could see setbacks in the sentiment recovery for the pharmaceutical industry, as market anticipation of drug price reform has now been raised. In reality, such reform is still likely to be relatively limited in scope, given the slim Senate majority, and also pushed back in time.
While average valuations have risen across equity markets, we do not believe we are at the point yet where they will put a damper on global equites upside. Not all markets are richly valued, and certainly not all stocks. The exceptional polarization that we have seen in stock performances over the last three quarters still allows investors to find attractive stocks at more reasonable valuations.
The exceptional polarization that we have seen in stock performances over the last three quarters still allows investors to find attractive stocks at more reasonable valuations
On a relative basis, we find more attractive investment opportunities in North Asia and Europe than in the US. Importantly, valuations are not sufficient to determine the attractiveness of a market. Relative earnings growth will continue to be the real discriminant, and this will be the key variable to monitor.
The polarization in market performance over the last year brings me to what I believe could become one of the most remarkable legacies of 2020. Last year was a year of extremes. The five largest stocks in the S&P 500 Index returned 64.5% versus an average return of 9.7% for the remaining 495 names. Last year also saw the highest number of daily moves over 1% and 2% in ten years, for the S&P 500 Index.
I cannot help but think that this has something to do with another record: retail investors’ participation in equities trading. According to Bloomberg Intelligence, individual stock trading through June 2020 was at a 10-year high, with retail trades estimated at 19.5% of all US order flow, up from 10.1% in 2010 and 14.9% in 2019. And this was not a US-only phenomenon. Retail trading accounts have been rising across the world.
While I do not have any clear proof that increased retail investor participation is a key driver behind the divergences in market behavior in 2020, what clearly appears in the market is a certain ‘headline effect’. Stocks that have a well-recognized brand, or a well-recognized story have seen unprecedented buying relative to the rest of the market.
This leaves an opportunity for investors that are willing to go the extra mile in researching stocks. For all the well-known new energy and new vehicle names, for all the well-known digital giants, there is a number of stocks that I like to call enablers, which are part of the chain of products or services which support those well-known players, as well as stocks that will be driven by those same trends, as they may make products that are not as glitzy, but that will be growing in parallel. That is where the ‘value’ is. Many of these stocks are still trading at reasonable valuations.
Both our Developed Markets and Emerging Markets teams have turned more positive on their respective equity markets. The common denominator is the upgrade of the earnings factor, as earnings revisions have significantly improved across developed and emerging markets and are now positive in both regions. Importantly, the earnings recovery appears broad based, as earnings revisions are improving across most sectors.
Earnings revisions have significantly improved across developed and emerging markets and are now positive in both regions
As vaccinations and better therapies help mitigate the extent of the Covid-driven economic lockdown, and activity continues to normalize, we expect further rotation from the Covid-beneficiary and Covid-defensive countries and stocks, toward countries and stocks that will benefit from the economic normalization. In the US, such rotation will be further supported by additional stimulus.
We are not concerned about the recent increase in US long-term yields, as these came on the back of the stimulus expectations and we don’t expect inflation to rise to levels that can stifle equity markets for the remainder of 2021. We continue to caution that selection remains key, as not all companies will be able to recover from the effects of extended lockdowns.
Overall, from a regional perspective we continue to favor emerging markets, which is our largest overweight position in our Global portfolios, followed by Europe. We find a few interesting opportunities in Japan, particularly in the technology sector. Within emerging markets, we continue to favor North Asia (China, Taiwan and South Korea).
In emerging markets, initial signs of Covid-19 deceleration and of a turnaround in economic momentum are starting to appear outside of North Asia. These will eventually warrant broadening our emerging markets positioning, and, on this basis, our Emerging Markets portfolios have increased their position in India. But these are relatively small moves and we would need to see further progress before we significantly increase our relative positioning outside of North Asia.
From a sector standpoint, our largest global overweight position is in technology, although we have cut further our positioning in the tech savvy high flyers in the US and Asia, as comparison bases are destined to become more challenging in the next two quarters and regulatory scrutiny is here to stay.
We have also taken additional profit from the Communications Services sector. We find more opportunities in Industrials, Consumer Discretionary, Specialty Materials and Healthcare, and have selectively added to Financials in the US and in emerging markets. Within healthcare, we have added to life science tools.
Last but not least, we continue to like sustainability as a theme. Besides the European ‘Green Deal’ and an increasing number of Asian markets pledging carbon neutrality by 2050-2060, the Biden administration with a united Congress should also trigger more investment in this area in the US.
The main risks to our outlook could be new virus outbreaks, or slower than expected vaccination campaigns, which we will continue to monitor.
Above all, we still find compelling opportunities in a market where polarized positioning was the name of the game in 2020. The jury is still out on whether this is due to increased retail participation. In the meantime, there is still plenty of upside potential for active investors willing to look beyond the headlines.
This information is for informational purposes only and should not be construed as an offer to sell or an invitation to buy any securities or products, nor as investment advice or recommendation.
The contents of this document have not been reviewed by the Monetary Authority of Singapore (“MAS”). Robeco Singapore Private Limited holds a capital markets services license for fund management issued by the MAS and is subject to certain clientele restrictions under such license.
An investment will involve a high degree of risk, and you should consider carefully whether an investment is suitable for you.
Warning/Important note: This website contains information which is only available to qualified investors as defined below. If you are not a qualified investor, please click “I Disagree” to leave the website.
By clicking on "I agree", I declare that:
1 - This website may only be accessed directly or indirectly by the following persons in Singapore:
1) “institutional investor” under section 304 of the Securities and Futures Act (Cap.289)(“SFA”), which means:
(i) the Government; (ii) a statutory board as may be prescribed by regulations made under section 341 of the SFA; (iii) an entity that is wholly and beneficially owned, whether directly or indirectly, by a central government of a country and whose principal activity is (A) to manage its own funds; (B) to manage the funds of the central government of that country (which may include the reserves of that central government and any pension or provident fund of that country); or (C) to manage the funds (which may include the reserves of that central government and any pension or provident fund of that country) of another entity that is wholly and beneficially owned, whether directly or indirectly, by the central government of that country; (iv) any entity (A) that is wholly and beneficially owned, whether directly or indirectly, by the central government of a country; and (B) whose funds are managed by an entity mentioned in sub-paragraph (iii); (v) a central bank in a jurisdiction other than Singapore; (vi) a central government in a country other than Singapore; (vii) an agency (of a central government in a country other than Singapore) that is incorporated or established in a country other than Singapore; (viii) a multilateral agency, international organisation or supranational agency as may be prescribed by regulations made under section 341 of the SFA; (ix) a bank that is licensed under the Banking Act (Cap.19); (x) a merchant bank that is approved as a financial institution under section 28 of the Monetary Authority of Singapore Act (Cap.186); (xi) a finance company that is licensed under the Finance Companies Act (Cap.108); (xii) a company or co-operative society that is licensed under the Insurance Act (Cap.142) to carry on insurance business in Singapore; (xiii) a company licensed under the Trust Companies Act (Cap.336); (xiv) a holder of a capital markets services licence; (xv) an approved exchange; (xvi) a recognised market operator; (xvii) an approved clearing house; (xviii) a recognised clearing house; (xix) a licensed trade repository; (xx) a licensed foreign trade repository; (xxi) an approved holding company; (xxii) a Depository as defined in section 81SF of the SFA; (xxiii) an entity or a trust formed or incorporated in a jurisdiction other than Singapore, which is regulated for the carrying on of any financial activity in that jurisdiction by a public authority of that jurisdiction that exercises a function that corresponds to a regulatory function of the Authority under this Act, the Banking Act (Cap.19), the Finance Companies Act (Cap.108), the Monetary Authority of Singapore Act (Cap.186), the Insurance Act (Cap.142), the Trust Companies Act (Cap.336) or such other Act as may be prescribed by regulations made under section 341 of the SFA; (xxiv) a pension fund, or collective investment scheme, whether constituted in Singapore or elsewhere; (xxv) a person (other than an individual) who carries on the business of dealing in bonds with accredited investors or expert investors; (xxvi) the trustee of such trust as the Authority may prescribe, when acting in that capacity; or; (xxvii) such other person as the Authority may prescribe.
2) “relevant person” under section 305(1) of the SFA, which means:
(i) An accredited investor; (ii) a corporation the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; (iii) a trustee of a trust the sole purpose of which is to hold investments and each beneficiary of which is an individual who is an accredited investor; (iv) an officer or equivalent person of the person making the offer (such person being an entity) or a spouse, parent, brother, sister, son or daughter of that officer or equivalent person; or (v) a spouse, parent, brother, sister, son or daughter of the person making the offer (such person being an individual).
3) any person who acquires the units [in a collective investment scheme] as principal if the offer is on terms that the units may only be required at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of units in a collective investment scheme, securities, securities-based derivatives contracts or other assets, and if the following condition is satisfied: (i) the offer is not accompanied by an advertisement making an offer or calling attention to the offer or intended offer; (ii) no selling or promotional expenses are paid or incurred in connection with the offer other than those incurred for administrative or professional services, or by way of commission or fee for services rendered by any of the persons specified in section 302B(1)(d)(i) to (vi) of the SFA; and (iii) no prospectus in respect of the offer has been registered by the Authority or, where a prospectus has been registered (A) the prospectus has eAccxpired pursuant to section 299 of the SFA; or (B) the person making the offer has before making the offer 1. informed the Authority by notice in writing of its intent to make the offer in reliance on the exemption under this subsection; and 2. taken reasonable steps to inform in writing the person to whom the offer is made that the offer is made in reliance on the exemption under this subsection.
4) Or otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
If you are not any of the types of persons described above, you are not authorized to enter this website and you should leave this website immediately.
2 Terms and Conditions
You acknowledge that you have read these Terms and Conditions (“Terms”) prior to accessing the website located at www.robeco.com/sg (“Website”) and you agree to be bound by the Terms. If you do not agree to all of the Terms, you are not an authorised user and you should not use the Website. The Website is owned by Robeco Singapore Private Limited (company registration number: UEN. 201541306Z), which is licensed by the Monetary Authority of Singapore (“MAS”) pursuant to the Securities and Futures Act (Cap.289) (“SFA”) of Singapore, and is managed by Robeco Singapore Private Limited and/or its affiliates (collectively, as “Robeco”). The Website is intended for and should be accessed by institutional investors or accredited investors (as defined under Section 4A of the SFA) of Singapore. The Website is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the Robeco to any registration or licensing requirement within such jurisdiction. It is your responsibility to observe all applicable laws, rules and regulations of any relevant jurisdiction. The content contained in the Website is owned by Robeco and/or its information providers and is protected by applicable copyrights, trademarks, service marks, and/or other intellectual property rights. You may not copy, distribute, modify, post, frame or link the Website, including any text, graphics, video, audio, software code, user interface, design or logos. You may not distribute, modify, transmit, reuse, repost, or use the content of the Website for public or commercial use, including all text, images, audio and/or video. Robeco may terminate your access to the Website for any reason, without prior notice. Neither Robeco, nor any of its associates, nor any director, officer or employee accepts any liability whatsoever for any loss arising directly or indirectly from the access of the Website. You agree to indemnity and hold Robeco, its associates, directors, officers or employees harmless against any and all claims, losses, liability, costs and expenses arising from your use of the Website due to violation of the Terms. Robeco reserves the right to change, modify, add or remove any parts of the Terms at any time and for any reason. The Terms shall deemed to be effective immediately upon posting. The Terms shall be governed by, and shall be construed in accordance with, the law of Singapore.
The Website has not been reviewed by the MAS. Accordingly, the Website may not be accessed directly or indirectly to persons in Singapore other than (i) to an institutional investor under Section 304 of the SFA, (ii) to a relevant person pursuant to Section 305(1), or any person pursuant to Section 305(2), and in accordance with the conditions specified in Section 305, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Nothing in the Website constitutes tax, accounting, regulatory, legal or investment advice. The Website is for informational purposes only and should not be construed as an offer to sell or an invitation to buy any securities or products, nor as investment advice or recommendation or for the purpose of soliciting any action in relation to Robeco’s businesses, or solicitation by anyone in any jurisdiction in which such an offer or solicitation is not authorised or to any person to whom it is unlawful to make such an offer and solicitation. Any reproduction or distribution of information from the Website, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited. By accessing to the Website, you agree to the foregoing.
The funds referred to in the Website are for information only. It is not a recommendation or investment advice, nor does it mean the funds is suitable for all investors. The contents of the website is not reviewed by the MAS. Any decision to participate in the funds should be made only after reviewing the sections regarding investment considerations, conflicts of interest, risk factors and the relevant Singapore selling restrictions. You should consult your professional adviser if you are in doubt about the stringent restrictions applicable to the use of the Website, regulatory status of the funds, applicable regulatory protection, associated risks and suitability of the funds to your objectives.
Any decisions made based on the information contained in the Website are the sole responsibility of yours. Any investments made or to be made shall be with your independent analyses based on your financial situation and objectives. The investments and strategies contained in the Website may not be suitable for all investors and are not guaranteed by Robeco.
Investment involves risks and may lose value. Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future. The value of your investments may fluctuate. Past performance is no indication of current or future performance. The Website may contain projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies and such projection or forecast is not indicative of the future. The information contained in the Website, including any data, projections and underlying assumptions are based upon certain assumptions, management forecasts and analysis of information available on an “as is” basis and without warranties of any kind, whether express or implied, and reflects prevailing conditions and Robeco’s views as of the date published or indicated, and maybe superseded by subsequent events or for other reasons. The information contained in the Website are accordingly subject to change at any time without notice and Robeco are under no obligation to notify you of any of these changes. Robeco expressly disclaims all liability for errors and omissions in the information presented in the Website and for the use or interpretation by others of information contained in the Website.
Robeco Singapore Private Limited holds a capital markets services licence for fund management issued by the MAS and is subject to certain clientele restrictions under such licence. An investment will involve a high degree of risk, and you should consider carefully whether an investment is suitable for you.